Decode health collaborates with quest diagnostics to speed biomarker discovery for drug and diagnostics development

Features nationally scaled rna sequencing and specimen collection for multiple sclerosis and non-alcoholic fatty liver disease with plans to expand nashville, tenn. , oct. 18, 2022 /prnewswire/ -- decode health, a healthcare ai company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology.
DGX Ratings Summary
DGX Quant Ranking